Funding
← Back to your selection

NVIDIA

Activity from announced rounds

Activity in this selectionUnited States · Sep 30, 2026 · Sep 1, 2026

NVIDIA builds the processors, systems and software used to train and run AI. Its startup relationships combine corporate investment with access to an accelerated-computing ecosystem.

Founders can approach its venture capital arm, NVentures, for investment in technology businesses. NVIDIA also operates Inception, a free programme offering technical training, selected hardware and software pricing benefits, and introductions through its VC Alliance.

Inception has no equity requirement. Applicants need an incorporated company, a working website, an actively involved founder and a use case for NVIDIA technology; a startup can join before it has revenue or starts using NVIDIA products. Membership provides development resources rather than an automatic investment.

Sources
Rounds participated in
6
Confirmed lead rounds
0
1 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$4.5B
5 disclosed · full round size, not this investor’s share

By stage

Series B2
Series C+2
Undisclosed2

By primary sector

AI2
Hardware2
Biotech1
Healthtech1

By country

United States6

Rounds

6 in this selection
GMI Cloud

GMI Cloud provides GPU computing, model inference and infrastructure for AI applications.

$223MSeries B
Participant
CScale

CScale develops optical interconnects that keep large AI computing systems communicating reliably.

$145MSeries C
Participant
Crusoe

AI infrastructure combining GPU cloud services, managed AI tools, large-scale data centers and modular AI factories for model developers and enterprises.

$3.9BSeries F (initial close; anticipated total)
Participant
Ayar Labs

Ayar Labs builds co-packaged optical interconnects that connect processors and GPUs in large AI systems.

$150MAdditional funding
Role not disclosed
Verily Health

An AI-native precision-health platform organizes complex health data for research, care and personalized health services.

UndisclosedMarch financing extension
Participant
Superluminal Medicines

Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.

$60MSeries B
Participant